

# Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/G285242E22DEN.html>

Date: November 2019

Pages: 83

Price: US\$ 2,000.00 (Single User License)

ID: G285242E22DEN

## Abstracts

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2019

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2019, provides an overview of the Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline landscape.

Wegener Polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores and fever. Predisposing factor includes age. Treatment includes immunosuppressive and corticosteroids.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 2, 1 and 4 respectively.

Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology).

The pipeline guide reviews pipeline therapeutics for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Granulomatosis with

Polyangiitis (Wegener Polyangiitis) (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Overview

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Therapeutics

Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Therapeutics

Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Companies Involved in  
Therapeutics Development

Bristol-Myers Squibb Co

Celltrion Inc

ChemoCentryx Inc

Generium

GlaxoSmithKline Plc

Humanigen Inc

iBio Inc

InflaRx NV

Insmed Inc

Nichi-Iko Pharmaceutical Co Ltd

Pharmapraxis

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Drug Profiles

abatacept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avacopan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HGEN-005 - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
IFX-1 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
INS-1007 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
mepolizumab - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
rituximab biobetter - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
rituximab biosimilar - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Dormant Projects  
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Discontinued Products  
Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Product Development  
Milestones  
Featured News & Press Releases  
Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1: Number of Products under Development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Products under Development by Companies, H2 2019

Table 4: Number of Products by Stage and Target, H2 2019

Table 5: Number of Products by Stage and Mechanism of Action, H2 2019

Table 6: Number of Products by Stage and Route of Administration, H2 2019

Table 7: Number of Products by Stage and Molecule Type, H2 2019

Table 8: Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Bristol-Myers Squibb Co, H2 2019

Table 9: Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Celltrion Inc, H2 2019

Table 10: Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by ChemoCentryx Inc, H2 2019

Table 11: Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Generium, H2 2019

Table 12: Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by GlaxoSmithKline Plc, H2 2019

Table 13: Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Humanigen Inc, H2 2019

Table 14: Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by iBio Inc, H2 2019

Table 15: Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by InflaRx NV, H2 2019

Table 16: Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Insmed Inc, H2 2019

Table 17: Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2019

Table 18: Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Pharmapraxi, H2 2019

Table 19: Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Dormant Projects, H2 2019

Table 20: Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Figure 1: Number of Products under Development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products by Targets, H2 2019

Figure 4: Number of Products by Stage and Targets, H2 2019

Figure 5: Number of Products by Mechanism of Actions, H2 2019

Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019

Figure 7: Number of Products by Routes of Administration, H2 2019

Figure 8: Number of Products by Stage and Routes of Administration, H2 2019

Figure 9: Number of Products by Molecule Types, H2 2019

Figure 10: Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

Bristol-Myers Squibb Co

Celltrion Inc

ChemoCentryx Inc

Generium

GlaxoSmithKline Plc

Humanigen Inc

iBio Inc

InflaRx NV

Insmed Inc

Nichi-Iko Pharmaceutical Co Ltd

Pharmapraxix



## I would like to order

Product name: Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/G285242E22DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G285242E22DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970